Publications by authors named "Agnes A Schubert-Tennigkeit"
Bimagrumab to improve recovery after hip fracture in older adults: a multicentre, double-blind, randomised, parallel-group, placebo-controlled, phase 2a/b trial.
Lorenz C Hofbauer Richard Witvrouw Zsuzsanna Varga Naofumi Shiota Malika Cremer Agnes Annette Schubert-Tennigkeit
Lancet Healthy Longev
May 2021
Article Synopsis
- The study focuses on older adults (60+) who have undergone hip fracture surgery, investigating the potential benefits of bimagrumab, a monoclonal antibody, in improving their recovery and muscle mass.
- Conducted across 50 research centers worldwide, the trial was double-blind and placebo-controlled, enrolling participants with specific criteria to ensure accurate results.
- The primary goal was to assess changes in lean body mass after 24 weeks, while secondary goals included evaluating gait speed and physical performance, alongside monitoring for safety and adverse effects.
Article Synopsis
- The study aimed to examine the long-term effects of bimagrumab over two years in patients with sporadic inclusion body myositis (sIBM), following an initial core study.
- Participants continued receiving bimagrumab or a placebo every four weeks, with the main outcomes being changes in the 6-minute walk distance and safety.
- Results showed that all treatment groups experienced a decline in mobility over time, with high rates of adverse events; however, bimagrumab did not result in significant clinical benefits, leading to the early termination of the extension study.
The objective of the FLIGHT3 study was to evaluate the long-term safety and efficacy of indacaterol/glycopyrrolate* (IND/GLY) versus an active comparator, IND, in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) over 52 weeks. FLIGHT3 was a multicenter, randomized, double-blind, parallel-group, 52-week study. Patients were randomized (1:1:1) to IND/GLY (27.
View Article and Find Full Text PDF